SILENCE THERAPEUTICS (SLNCF) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 29 36 sessions, August 4, 2025 to August 18, 2026
- Largest daily move
- +200% close of August 10, 2026
- 1-year change
- +226.4% closing prices, August 4, 2025 to August 18, 2026
- 5-year change
- -29.9% closing prices, August 18, 2021 to August 18, 2026
Company Description
SILENCE THERAPEUTICS (OTC: SLNCF) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $226.7M.
SLNCF has gained 226.4% over the past year. The last closing price was $5.50.
For FY2025, SILENCE THERAPEUTICS reported revenue of $559K with net income of -$88.6M and diluted earnings per share of -$0.63. The company operates at a net profit margin of -15851.5%.
This page collects what Stock Titan holds for SLNCF, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
SILENCE THERAPEUTICS (SLNCF) closed at $5.50 on August 18, 2026. Over the past 12 months, the price has gained 226.4%.
SLNCF Metrics & Rankings
Price returns through August 18, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SILENCE THERAPEUTICS has 3 recent news articles. Key topics include management. View all SLNCF news →
SEC Filings
SILENCE THERAPEUTICS has filed 5 recent SEC filings, including 1 Form 4, 1 Form SCHEDULE 13D/A, 1 Form SCHEDULE 13G/A, 1 Form 8-K. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SLNCF SEC filings →
Financial Highlights
SILENCE THERAPEUTICS generated $559K in revenue in FY2025, retaining a 61.5% gross margin, operating income reached -$91.1M (-16292.8% operating margin), and net income was -$88.6M, reflecting a -15851.5% net profit margin. Diluted earnings per share stood at -$0.63. The company generated -$62.3M in operating cash flow. With a current ratio of 8.72, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in SILENCE THERAPEUTICS (SLNCF) currently stands at 2.4 thousand shares, up 351.9% from the previous reporting period, representing 0.0% of the float. Since January 2026, short interest has increased by 211.3%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for SILENCE THERAPEUTICS (SLNCF) currently stands at 4.5 days, up 260.8% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 162.2% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
SLNCF Company Profile & Sector Positioning
SILENCE THERAPEUTICS (SLNCF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing SLNCF often look at related companies in the same sector, including BIOINVENT INTL NEW (BOVNF), HANSA MEDICAL AB (HNSBF), ORYZON GENOMICS SA (ORYZF), NERVGEN PHARMA CORP (NGENF), and ADOCIA (ADOCY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SLNCF's relative position within its industry.